Koca Kalkan Ilkay, Koycu Buhari Gozde, Ates Hale, Basa Akdogan Buket, Erdem Ozdedeoglu Ozlem, Aksu Kurtulus, Oner Erkekol Ferda
Department of Immunology and Allergy, Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Turkey.
Division of Immunology and Allergy, Department of Chest Diseases, Ankara Yıldırım Beyazıt University School of Medicine, Ankara, Turkey.
J Asthma Allergy. 2021 Jan 22;14:47-58. doi: 10.2147/JAA.S292442. eCollection 2021.
Local anesthetics (LA) are widely used and adverse drug reactions (ADR) occur in 2.5-10%, but hypersensitivity reactions are rare (ranging between 0% and 4.3%). Risk is so overestimated causing too many allergy clinic referrals. There are limited and also conflicting results over the management of LA allergy. We aimed to find out who should be referred to an allergy clinic for a LA allergy testing, to define the subjects with an increased risk of LA allergy and to assess the need for testing for identifying alternative LA.
We performed a retrospective study of patients referred to our clinic for diagnostic workup of LA hypersensitivity from 2006 to 2020.
In our cohort of 398 patients, tests were positive in 14 (3.52%) of them. Personal history of ADR with LA was the only independent risk factor for positive test (RR=4.007, p=0.033). Presence of generalized cutaneous symptoms and hypotension during past reaction were independent predictors of positive test (RR=9.043, p=0.021 and RR=10.445, p=0.038, respectively). The negative predictive value of intradermal test at dilution of 1:100 for immediate-type reaction was high (97.56%). Also, we demonstrated cross-reactivity within the amide-group LAs and co-occurrence of immediate- and delayed-type reactions.
Only patients with an LA-induced ADR should be referred to an allergy clinic. History of generalized cutaneous symptoms and/or hypotension during the reaction may define subjects with an increased risk of LA allergy. A stepwise test procedure may start with skin tests especially for these patients with increased risk factors. In presence of LA allergy, alternative LA should always be confirmed by performing a challenge test.
局部麻醉药(LA)被广泛使用,药物不良反应(ADR)发生率为2.5%-10%,但过敏反应罕见(0%-4.3%)。风险被高估,导致过多患者被转诊至过敏诊所。关于LA过敏的管理,研究结果有限且相互矛盾。我们旨在确定哪些患者应被转诊至过敏诊所进行LA过敏检测,明确LA过敏风险增加的人群,并评估检测以确定替代LA的必要性。
我们对2006年至2020年转诊至我院诊所进行LA过敏诊断检查的患者进行了回顾性研究。
在我们的398例患者队列中,14例(3.52%)检测呈阳性。LA所致ADR的个人史是检测呈阳性的唯一独立危险因素(RR=4.007,p=0.033)。既往反应期间出现全身性皮肤症状和低血压是检测呈阳性的独立预测因素(分别为RR=9.043,p=0.021和RR=10.445,p=0.038)。1:100稀释度的皮内试验对速发型反应的阴性预测值较高(97.56%)。此外,我们证明了酰胺类LA之间存在交叉反应以及速发型和迟发型反应并存。
只有LA诱发ADR的患者才应被转诊至过敏诊所。反应期间出现全身性皮肤症状和/或低血压史可能表明LA过敏风险增加。对于这些有增加的危险因素的患者,逐步检测程序可从皮肤试验开始。如果存在LA过敏,始终应通过进行激发试验来确认替代LA。